Corporate Development

Since our founding, Geron has focused on strong science and the pursuit of R&D excellence to discover and develop innovative, first-in-class therapies for the treatment of cancer as evidenced through the development of our first-in-class telomerase inhibitor, imetelstat, initially being developed in hematologic myeloid malignancies.

We enjoy working with like-minded partners who want to join forces to transform the lives of patients with hematologic malignancies by delivering novel therapeutics such as imetelstat to change the course of their disease. We are interested in development and commercial stage strategic partnerships and collaborations that bring complementary capabilities and programs to realize the full potential of imetelstat to address unmet medical needs on a global basis.

To contact our Corporate Development team, please send an e-mail to

Scientific Collaborators

Share our passion and vision. Academic research has an important role throughout the development of new medicines. Our collaborations with many scientific and clinical experts have led to key contributions to the scientific understanding of telomere and telomerase biology, and our telomerase inhibitor, imetelstat. We invite you to partner with us in our quest to develop this novel therapy and make a difference in patients’ lives. Please send all inquiries to: